APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting DPP-4 Inhibitor Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting DPP-4 Inhibitor Drug Market Outlook and Growth Opportunities 2026

27 December 2025196 pages

Choose your research edition.

Industry ResearchLong-acting DPP-4 Inhibitor Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting DPP-4 Inhibitor Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Long-acting DPP-4 Inhibitor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting DPP-4 Inhibitor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting DPP-4 Inhibitor Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Long-acting DPP-4 Inhibitor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting DPP-4 Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting DPP-4 Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting DPP-4 Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting DPP-4 Inhibitor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting DPP-4 Inhibitor Drug market include Easton Biopharmaceuticals, Takeda Pharmaceutical, Merck & Co, Kelun Pharmaceutical, Haisco Pharmaceutical, Beacon Pharma, Baiji Dichang Pharmaceutical and Furiex, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Long-acting DPP-4 Inhibitor Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting DPP-4 Inhibitor Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting DPP-4 Inhibitor Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Long-acting DPP-4 Inhibitor Drug market.

Long-acting DPP-4 Inhibitor Drug Segment by Company

Easton Biopharmaceuticals

Takeda Pharmaceutical

Merck & Co

Kelun Pharmaceutical

Haisco Pharmaceutical

Beacon Pharma

Baiji Dichang Pharmaceutical

Furiex

Long-acting DPP-4 Inhibitor Drug Segment by Type

Weekly

Biweekly

Long-acting DPP-4 Inhibitor Drug Segment by Application

Hospital

Clinic

Others

Long-acting DPP-4 Inhibitor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting DPP-4 Inhibitor Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Long-acting DPP-4 Inhibitor Drug key companies, revenue, market share, and recent developments.

3. To split the Long-acting DPP-4 Inhibitor Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Long-acting DPP-4 Inhibitor Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting DPP-4 Inhibitor Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting DPP-4 Inhibitor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting DPP-4 Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting DPP-4 Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting DPP-4 Inhibitor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting DPP-4 Inhibitor Drug industry.

Chapter 3: Detailed analysis of Long-acting DPP-4 Inhibitor Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Long-acting DPP-4 Inhibitor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Long-acting DPP-4 Inhibitor Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting DPP-4 Inhibitor Drug Industry Trends Table 2. Long-acting DPP-4 Inhibitor Drug Industry Drivers Table 3. Long-acting DPP-4 Inhibitor Drug Industry Opportunities and Challenges Table 4. Long-acting DPP-4 Inhibitor Drug Industry Restraints Table 5. Global Long-acting DPP-4 Inhibitor Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting DPP-4 Inhibitor Drug Revenue Share by Company (2021-2026) Table 7. Global Long-acting DPP-4 Inhibitor Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Long-acting DPP-4 Inhibitor Drug Key Company Manufacturing Base & Headquarters Table 9. Global Long-acting DPP-4 Inhibitor Drug Company, Product Type & Application Table 10. Global Long-acting DPP-4 Inhibitor Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Long-acting DPP-4 Inhibitor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Weekly Table 15. Significant Companies of Biweekly Table 16. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type (2021-2026) Table 20. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application (2021-2026) Table 28. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application (2027-2032) Table 29. Global Long-acting DPP-4 Inhibitor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Region (2021-2026) Table 32. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Region (2027-2032) Table 34. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Long-acting DPP-4 Inhibitor Drug Sales Value Market Share by Country (2021-2026) Table 37. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Long-acting DPP-4 Inhibitor Drug Sales Value Market Share by Country (2027-2032) Table 39. Easton Biopharmaceuticals Company Information Table 40. Easton Biopharmaceuticals Business Overview Table 41. Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 43. Easton Biopharmaceuticals Recent Development Table 44. Takeda Pharmaceutical Company Information Table 45. Takeda Pharmaceutical Business Overview Table 46. Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 48. Takeda Pharmaceutical Recent Development Table 49. Merck & Co Company Information Table 50. Merck & Co Business Overview Table 51. Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Merck & Co Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 53. Merck & Co Recent Development Table 54. Kelun Pharmaceutical Company Information Table 55. Kelun Pharmaceutical Business Overview Table 56. Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 58. Kelun Pharmaceutical Recent Development Table 59. Haisco Pharmaceutical Company Information Table 60. Haisco Pharmaceutical Business Overview Table 61. Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 63. Haisco Pharmaceutical Recent Development Table 64. Beacon Pharma Company Information Table 65. Beacon Pharma Business Overview Table 66. Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 68. Beacon Pharma Recent Development Table 69. Baiji Dichang Pharmaceutical Company Information Table 70. Baiji Dichang Pharmaceutical Business Overview Table 71. Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 73. Baiji Dichang Pharmaceutical Recent Development Table 74. Furiex Company Information Table 75. Furiex Business Overview Table 76. Furiex Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Furiex Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 78. Furiex Recent Development Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Long-acting DPP-4 Inhibitor Drug Product Image Figure 2. Global Long-acting DPP-4 Inhibitor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting DPP-4 Inhibitor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting DPP-4 Inhibitor Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Weekly Image Figure 8. Biweekly Image Figure 9. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Long-acting DPP-4 Inhibitor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application (2021-2032) Figure 18. Global Long-acting DPP-4 Inhibitor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Weekly
  • Biweekly
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Easton Biopharmaceuticals
  • Takeda Pharmaceutical
  • Merck & Co
  • Kelun Pharmaceutical
  • Haisco Pharmaceutical
  • Beacon Pharma
  • Baiji Dichang Pharmaceutical
  • Furiex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting DPP-4 Inhibitor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting DPP-4 Inhibitor Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Long-acting DPP-4 Inhibitor Drug Market Dynamics
  1. 2.1 Long-acting DPP-4 Inhibitor Drug Industry Trends
  2. 2.2 Long-acting DPP-4 Inhibitor Drug Industry Drivers
  3. 2.3 Long-acting DPP-4 Inhibitor Drug Industry Opportunities and Challenges
  4. 2.4 Long-acting DPP-4 Inhibitor Drug Industry Restraints
3 Long-acting DPP-4 Inhibitor Drug Market by Company
  1. 3.1 Global Long-acting DPP-4 Inhibitor Drug Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting DPP-4 Inhibitor Drug Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting DPP-4 Inhibitor Drug Company Ranking (2024-2026)
  4. 3.4 Global Long-acting DPP-4 Inhibitor Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Long-acting DPP-4 Inhibitor Drug Company Product Type and Application
  6. 3.6 Global Long-acting DPP-4 Inhibitor Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Long-acting DPP-4 Inhibitor Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Long-acting DPP-4 Inhibitor Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Long-acting DPP-4 Inhibitor Drug Market by Type
  1. 4.1 Long-acting DPP-4 Inhibitor Drug Type Introduction
  2. 4.1.1 Weekly
  3. 4.1.2 Biweekly
  4. 4.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Type
  5. 4.2.1 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type (2021-2032)
5 Long-acting DPP-4 Inhibitor Drug Market by Application
  1. 5.1 Long-acting DPP-4 Inhibitor Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Application
  6. 5.2.1 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application (2021-2032)
6 Long-acting DPP-4 Inhibitor Drug Regional Value Analysis
  1. 6.1 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032)
  7. 6.3.2 North America Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032)
  16. 6.6.2 South America Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Sales Value Share by Country, 2025 VS 2032
7 Long-acting DPP-4 Inhibitor Drug Country-level Value Analysis
  1. 7.1 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Long-acting DPP-4 Inhibitor Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Long-acting DPP-4 Inhibitor Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Long-acting DPP-4 Inhibitor Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Long-acting DPP-4 Inhibitor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Easton Biopharmaceuticals
  2. 8.1.1 Easton Biopharmaceuticals Company Information
  3. 8.1.2 Easton Biopharmaceuticals Business Overview
  4. 8.1.3 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Portfolio
  6. 8.1.5 Easton Biopharmaceuticals Recent Developments
  7. 8.2 Takeda Pharmaceutical
  8. 8.2.1 Takeda Pharmaceutical Company Information
  9. 8.2.2 Takeda Pharmaceutical Business Overview
  10. 8.2.3 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  12. 8.2.5 Takeda Pharmaceutical Recent Developments
  13. 8.3 Merck & Co
  14. 8.3.1 Merck & Co Company Information
  15. 8.3.2 Merck & Co Business Overview
  16. 8.3.3 Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co Long-acting DPP-4 Inhibitor Drug Product Portfolio
  18. 8.3.5 Merck & Co Recent Developments
  19. 8.4 Kelun Pharmaceutical
  20. 8.4.1 Kelun Pharmaceutical Company Information
  21. 8.4.2 Kelun Pharmaceutical Business Overview
  22. 8.4.3 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  24. 8.4.5 Kelun Pharmaceutical Recent Developments
  25. 8.5 Haisco Pharmaceutical
  26. 8.5.1 Haisco Pharmaceutical Company Information
  27. 8.5.2 Haisco Pharmaceutical Business Overview
  28. 8.5.3 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  30. 8.5.5 Haisco Pharmaceutical Recent Developments
  31. 8.6 Beacon Pharma
  32. 8.6.1 Beacon Pharma Company Information
  33. 8.6.2 Beacon Pharma Business Overview
  34. 8.6.3 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Portfolio
  36. 8.6.5 Beacon Pharma Recent Developments
  37. 8.7 Baiji Dichang Pharmaceutical
  38. 8.7.1 Baiji Dichang Pharmaceutical Company Information
  39. 8.7.2 Baiji Dichang Pharmaceutical Business Overview
  40. 8.7.3 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  42. 8.7.5 Baiji Dichang Pharmaceutical Recent Developments
  43. 8.8 Furiex
  44. 8.8.1 Furiex Company Information
  45. 8.8.2 Furiex Business Overview
  46. 8.8.3 Furiex Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Furiex Long-acting DPP-4 Inhibitor Drug Product Portfolio
  48. 8.8.5 Furiex Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst